EndoDNA, a company specializing in precision health intelligence, has introduced BIOS, an innovative and patented clinical decision-support platform designed exclusively for licensed healthcare professionals. Replacing the company's previous interpretation engine, myDNALive, BIOS provides practitioners in functional, integrative, regenerative, hormone optimization, and longevity medicine with a dynamic, long-term view of a patient's biological profile.
BIOS—short for Biomedical Reasoning and Adaptive Inference Network—takes precision medicine beyond traditional static genetic reports. Instead of offering one-time insights, the platform continuously integrates genomic information, biomarkers, lifestyle factors, symptoms, and other patient data into a unified, evolving clinical dashboard.
According to Len May, Founder and CEO of EndoDNA, healthcare providers have access to unprecedented amounts of biological data but often lack practical tools to translate that information into actionable care strategies. BIOS was developed to bridge this gap by converting complex biological information into structured clinical insights that adapt as patient conditions change, enabling more informed and consistent treatment decisions.
A Pathway-Centered Approach to Genomic Analysis
Unlike many consumer DNA services and generic artificial intelligence platforms that focus on interpreting individual single-nucleotide polymorphisms (SNPs), BIOS evaluates interconnected biological pathways. This systems-based approach allows practitioners to better understand how genetic factors influence overall health.
The platform analyzes key physiological areas, including:
Hormone metabolism and metabolic regulation Inflammatory processes and stress-response mechanisms Neurotransmitter activity and cognitive performance BIOS—short for Biomedical Reasoning and Adaptive Inference Network—takes precision medicine beyond traditional static genetic reports. Instead of offering one-time insights, the platform continuously integrates genomic information, biomarkers, lifestyle factors, symptoms, and other patient data into a unified, evolving clinical dashboard.
According to Len May, Founder and CEO of EndoDNA, healthcare providers have access to unprecedented amounts of biological data but often lack practical tools to translate that information into actionable care strategies. BIOS was developed to bridge this gap by converting complex biological information into structured clinical insights that adapt as patient conditions change, enabling more informed and consistent treatment decisions.
A Pathway-Centered Approach to Genomic Analysis
Unlike many consumer DNA services and generic artificial intelligence platforms that focus on interpreting individual single-nucleotide polymorphisms (SNPs), BIOS evaluates interconnected biological pathways. This systems-based approach allows practitioners to better understand how genetic factors influence overall health.
The platform analyzes key physiological areas, including:
Overall, BIOS evaluates approximately one million validated genetic variants across 21 biological systems and actively manages 214 curated pathways to support real-time clinical decision-making.
Four Integrated Intelligence Networks
Rather than evaluating isolated data points, BIOS uses four interconnected memory networks that collectively create a comprehensive and continuously updated patient profile:
World Network – Incorporates large-scale genomic research and evidence from established resources such as biobanks, CPIC, and PharmGKB.
Experience Network – Leverages aggregated clinical case data to identify interventions that have produced favorable outcomes in similar patient populations.
Opinion Network – Captures practitioner observations, notes, and custom adjustments to personalize recommendations.
Observation Network – Monitors patient-reported outcomes alongside biomarker and laboratory trends over time.
Through a HIPAA-compliant interface, licensed healthcare providers can order DNA testing, generate multiple specialized reports from existing genotype data, integrate laboratory and biomarker information, evaluate pharmacogenomic interactions, and perform natural-language searches of genomic datasets.
Available reporting modules include:
Female and Male Regenerative Health NeuroDNA Cognitive and Neurological Health Nutrigenomics and Metabolic Pathway Analysis Endocannabinoid System (ECS) Assessments Hormone Optimization and Longevity Pathway Analysis Four Integrated Intelligence Networks
Rather than evaluating isolated data points, BIOS uses four interconnected memory networks that collectively create a comprehensive and continuously updated patient profile:
World Network – Incorporates large-scale genomic research and evidence from established resources such as biobanks, CPIC, and PharmGKB.
Experience Network – Leverages aggregated clinical case data to identify interventions that have produced favorable outcomes in similar patient populations.
Opinion Network – Captures practitioner observations, notes, and custom adjustments to personalize recommendations.
Observation Network – Monitors patient-reported outcomes alongside biomarker and laboratory trends over time.
Through a HIPAA-compliant interface, licensed healthcare providers can order DNA testing, generate multiple specialized reports from existing genotype data, integrate laboratory and biomarker information, evaluate pharmacogenomic interactions, and perform natural-language searches of genomic datasets.
Available reporting modules include:
Dr. Allen Lawrence, MA, MD, PhD, noted that while clinicians have long struggled with the challenge of interpreting vast quantities of biological data, BIOS provides a practical framework for transforming that information into meaningful clinical action. By converting genomic and biological inputs into organized, actionable intelligence, the platform supports a more scalable model of precision medicine that enhances decision-making, patient engagement, and individualized care delivery.
Proven Accuracy and Ongoing Innovation
Since its inception, EndoDNA has supported more than 10,000 patients across over nine countries through partnerships with CAP- and CLIA-accredited laboratories. Utilizing Illumina next-generation sequencing technology, the company reports a genotyping accuracy rate of 99.6%.
EndoDNA's intellectual property portfolio includes more than ten issued and pending patents. Among these are a patented methodology for genotyping the endocannabinoid system (ECS) and a proprietary machine-learning framework designed to predict treatment effectiveness using genetic and biometric information.
BIOS is available immediately to licensed healthcare professionals as both a clinical decision-support solution and a research-focused platform.
Proven Accuracy and Ongoing Innovation
Since its inception, EndoDNA has supported more than 10,000 patients across over nine countries through partnerships with CAP- and CLIA-accredited laboratories. Utilizing Illumina next-generation sequencing technology, the company reports a genotyping accuracy rate of 99.6%.
EndoDNA's intellectual property portfolio includes more than ten issued and pending patents. Among these are a patented methodology for genotyping the endocannabinoid system (ECS) and a proprietary machine-learning framework designed to predict treatment effectiveness using genetic and biometric information.
BIOS is available immediately to licensed healthcare professionals as both a clinical decision-support solution and a research-focused platform.